EGFR and non-small cell lung carcinoma: They have shown superior progression free survival when compared to cytotoxic chemotherapy and are currently approved for first line treatment of advanced EGFR mutant NSCLC where the commonest subtypes include the mutant L858R (40%) or exon 19 deletions (40%)1.